ANPAC Bio-Medical launching new facility in California.
Meet the People Who Are Changing the Game
The Leadership Team
Dr. Herbert Yu
Co-Founder/Chief Science Officer
Dr. Herbert Yu is an M.D, with a Ph.D. in Clinical Biochemistry from University of Toronto. He is a highly acclaimed research director and professor in epidemiology and cancer research at Yale University and University Hawaii.
Dr. Chris Yu
Co-Founder/Chief Executive Officer
Dr. Chris Yu attended medical school before changing his studies to Physics and earning his Ph.D. from Pennsylvania State University. He is a successful Fortune 500 business executive, innovative engineer, and pioneering inventor.

Our Worldwide Team

Anpac Bio employs nearly 70 creative and innovative scientists, researchers, engineers, and business professionals worldwide. Educated at internationally-acclaimed, universities and educational institutions (such as Yale University); and recruited from Fortune 500, NYSE- and NASDAQ-listed corporations (including General Electric, Bayer, Roche, etc.); Anpac employees are recognized leaders in the medical device industry and technology industries.

Collectively, Anpac Bio’s employees are the inventors of over 500 patent applications. The company’s multi-disciplinary, collaborative approach results in a strong track record of successful innovation, leading to laboratory trials, pilot plant development, full-scale manufacturing, and market growth.

Anpac Bio-Medical’s scientists have been invited to share the company’s breakthrough CDA research results at respected international health and science events such as the Nobel Prize Laureate Summit on Biomedical Science, the American Society of Clinical Oncology, and the international ASCO Breast Cancer Symposium.

Team Culture

Anpac Bio is mission-focused on developing tools for early disease detection. As part of that mission, the company promotes a healthy corporate culture of creativity, teamwork, balance, and commitment to excellence, family, and social responsibility.

The company’s unique, cross-disciplinary approach combines medicine, biochemistry, and engineering—to achieve vastly superior early disease screening and detection technology.